Please login to the form below

Not currently logged in
Email:
Password:

Hugh Cole joins Jounce Therapeutics as chief business officer

He also takes up a head of corporate development role at the US firm

Hugh ColeUS clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development.

Cole brings over 25 years’ experience in biotech including business development, corporate strategy, R&D, alliance management, commercial planning and execution and corporate leadership.

He has most recently served as chief business officer at Ariad Pharmaceuticals, where he led several business development transactions for the company and helped develop and implement Ariad’s new corporate strategy.

Richard Murray, chief executive officer, Jounce Therapeutics, said: “Hugh has a tremendous experience and a great track record in the pharmaceutical and biotechnology industries, with robust knowledge of oncology pipeline progression and commercial strategy.

“We are thrilled to welcome him to Jounce at a critical point in our drug development process.”

In addition to his former role at Ariad, Cole was former senior vice president, strategic planning and programme management at Shire, where he oversaw the company’s portfolio management and rare disease processes.

He has also held roles for Oscient Pharmaceuticals, The Wilkerson Group and Fred Alger Management.

Murray added: “As we continue with the clinical development of our lead programme, JTX-2011, and progress our pipeline of innovative immunotherapies, it will be crucial to have Hugh’s business, strategic leadership and management expertise.”

24th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics